logo
  • About
  • R&D
  • Pipeline
  • Investors
  • News
  • Contact
  • Primary Sclerosing Cholangitis
  • Nonalcoholic Steatohepatitis (NASH)
  • (NASH) דלקת כבד על רקע שומני
Investor Relations

Investor Relations

  • Overview
  • News & Events
    • News
    • Events
    • Presentations
    • Contact IR
    • Email Alerts
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • Stock
    • Stock Quote & Chart
    • Historical Stock Price
    • Analyst Coverage
  • Corporate Governance
    • Board Committees
    • Board of Directors
    • Leadership
    • Documents
    • SEC Filings

    • Annual Reports

    • Quarterly Results

NASDAQCMMB
YearTrailing 12-MonthsCalendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2013Calendar Year 2012Calendar Year 2011
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Mergers & AcquisitionsProxy & Information StatementsOther
FormDescriptionDateFormat
SC 13D/AAmendment to a SC 13D filingJan 5, 2023Open Amendment to a SC 13D filing in HTML.Open Amendment to a SC 13D filing in DOC file.Open Amendment to a SC 13D filing in PDF file.Open Amendment to a SC 13D filing in XLS file.
SC 13D/AAmendment to a SC 13D filingNov 17, 2022Open Amendment to a SC 13D filing in HTML.Open Amendment to a SC 13D filing in DOC file.Open Amendment to a SC 13D filing in PDF file.Open Amendment to a SC 13D filing in XLS file.

Investor Relations

Chemomab Therapeutics Ltd.

Kiryat Atidim, Building 7
Tel Aviv, Israel 6158002

Follow us on

Subscribe to Alerts

Irina Koffler

LifeSci Advisors, LLC

IR@Chemomab.com

Phone: +1-917-734-7387

Barbara Lindheim

Consulting Vice President

Investor & Public Relations

barbara@chemomab.com

Phone: +1-917-355-9234

Copyright © Chemomab. All rights reserved.

Privacy Policy Terms of Service

Designed and built by Studio Praktik